Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1974 1
1979 1
1981 3
1982 1
1983 14
1984 20
1985 41
1986 76
1987 88
1988 112
1989 175
1990 349
1991 689
1992 1119
1993 1541
1994 2062
1995 2323
1996 2661
1997 3083
1998 3274
1999 3473
2000 3773
2001 3917
2002 3960
2003 3998
2004 4036
2005 4011
2006 3984
2007 4034
2008 4138
2009 4095
2010 4529
2011 4818
2012 4972
2013 5042
2014 5176
2015 5347
2016 5023
2017 4947
2018 4807
2019 4758
2020 4779
2021 4624
2022 4375
2023 3914
2024 3715
2025 4053
2026 2850
2027 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126,841 results

Results by year

Filters applied: . Clear all
Page 1
CDK5: an oncogene or an anti-oncogene: location location location.
Nikhil K, Shah K. Nikhil K, et al. Mol Cancer. 2023 Nov 23;22(1):186. doi: 10.1186/s12943-023-01895-8. Mol Cancer. 2023. PMID: 37993880 Free PMC article. Review.
The emerging theme suggests that CDK5's role as an oncogene or anti-oncogene depends upon its subcellular localization. CDK5 mostly acts as an oncogene, but in gastric cancer, it is a tumor suppressor due to its unique nuclear localizatio …
The emerging theme suggests that CDK5's role as an oncogene or anti-oncogene depends upon its subcellular localization. …
Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review.
Kontomanolis EN, Koutras A, Syllaios A, Schizas D, Mastoraki A, Garmpis N, Diakosavvas M, Angelou K, Tsatsaris G, Pagkalos A, Ntounis T, Fasoulakis Z. Kontomanolis EN, et al. Anticancer Res. 2020 Nov;40(11):6009-6015. doi: 10.21873/anticanres.14622. Anticancer Res. 2020. PMID: 33109539 Review.
Angiogenesis and angiogenic factors found to be expressed in tumors and may play a key role in tumor formation and development. Tumor-suppressor genes block the growth of cancer and contribute to the normal development of cells. This article highlights …
Angiogenesis and angiogenic factors found to be expressed in tumors and may play a key role in tumor formation and development. Tu …
Anti-oncogene and tumor suppressor gene therapy--examples from a lung cancer animal model.
Zhang WW, Roth JA. Zhang WW, et al. In Vivo. 1994 Nov-Dec;8(5):755-69. In Vivo. 1994. PMID: 7727723 Review.
Discovery of the genetic basis of cancer has indicated that cancer is a disease of genes. Among a variety of approaches to gene therapy of cancer, anti-oncogene and tumor suppressor gene therapy of cancer are the two strategies that aim at corre …
Discovery of the genetic basis of cancer has indicated that cancer is a disease of genes. Among a variety of approaches to gene thera …
[Hereditary neuroendocrine neoplasms].
Chouchane A, Marinoni I, Perren A. Chouchane A, et al. Pathologie (Heidelb). 2026 Sep;47(5):341-349. doi: 10.1007/s00292-026-01572-9. Epub 2026 May 28. Pathologie (Heidelb). 2026. PMID: 42207253 Review. German.
Hereditary neuroendocrine neoplasms (NENs) are the basis of over 10% of all neuroendocrine tumors. They result from germline mutations in tumor suppressor genes or proto-oncogenes.Compared to sporadic forms, hereditary NENs usually manifest at a younger age. …
Hereditary neuroendocrine neoplasms (NENs) are the basis of over 10% of all neuroendocrine tumors. They result from germline mutations in …
GPRASP1 is a candidate anti-oncogene and correlates with immune microenvironment and immunotherapeutic efficiency in head and neck cancer.
Zhang T, Liu G, Zhang J, Chen S, Deng Z, Xie M. Zhang T, et al. J Oral Pathol Med. 2023 Mar;52(3):232-244. doi: 10.1111/jop.13376. Epub 2022 Nov 4. J Oral Pathol Med. 2023. PMID: 36264603
Finally, immunophenoscore and tumor immune dysfunction and exclusion analysis demonstrated that GPRASP1 expression levels can accurately predict the immunotherapeutic response. ...Evaluating GPRASP1 expression will aid in the characterization of tumor microenvironme …
Finally, immunophenoscore and tumor immune dysfunction and exclusion analysis demonstrated that GPRASP1 expression levels can accurat …
[Cell cycle regulation by anti-oncogene].
Akiyama T. Akiyama T. Tanpakushitsu Kakusan Koso. 1994 Sep;39(12):2158-62. Tanpakushitsu Kakusan Koso. 1994. PMID: 7938611 Review. Japanese. No abstract available.
Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer.
Vafaei R, Khaki Z, Salehi M, Jalili N, Esmailinejad MR, Muhammadnajad A, Nassiri SM, Vajhi A, Kalbolandi SM, Mirzaei R, Farahmand L. Vafaei R, et al. Invest New Drugs. 2023 Apr;41(2):226-239. doi: 10.1007/s10637-023-01354-7. Epub 2023 Apr 1. Invest New Drugs. 2023. PMID: 37004643
Herein, we examined its preclinical efficacy for the reduction of tumor growth, invasiveness and angiogenesis in vitro and in vivo. Expressed anti-MET scFv demonstrated high binding capacity (48.8%) toward MET-overexpressing cancer cells. ...Grafted breast tumors in …
Herein, we examined its preclinical efficacy for the reduction of tumor growth, invasiveness and angiogenesis in vitro and in vivo. E …
126,841 results
You have reached the last available page of results. Please see the User Guide for more information.